Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer
27 Dezembro 2018 - 9:30AM
Business Wire
Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of people with cancer, today announced that company management will
host a conference call on Thursday, Jan. 3, 2018 at 8:30 a.m. ET to
review updated data from its Phase 3 VISTA Trial of Vicinium™ for
the treatment of patients with high-grade non-muscle invasive
bladder cancer who have been previously treated with bacillus
Calmette-Guérin.
To participate in the conference call, please dial (844)
831-3025 (domestic) or (315) 625-6887 (international) and refer to
conference ID 4263106. The webcast can be accessed in the Investor
Relations section of the company's website at www.sesenbio.com. The
replay of the webcast will be available in the investor section of
the company’s website at www.sesenbio.com for 60 days following the
call.
About Sesen BioSesen Bio, Inc. is a late-stage clinical
company advancing targeted fusion protein therapeutics for the
treatment of cancer. The company’s lead program, Vicinium™, also
known as VB4-845, is currently in a Phase 3 registration trial, the
VISTA Trial, for the treatment of high-grade non-muscle invasive
bladder cancer. Twelve-month data from all patients in the trial
are anticipated in mid-2019. Vicinium incorporates a
tumor-targeting antibody fragment and a protein cytotoxic payload
into a single protein molecule designed to selectively and
effectively kill cancer cells while minimizing toxicity to
non-cancerous bladder cells. For more information, please visit the
company’s website at www.sesenbio.com.
Cautionary Note on Forward-Looking StatementsAny
statements in this press release about future expectations, plans
and prospects for the Company, the Company’s strategy, future
operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and conduct of clinical
trials, expectations regarding our ongoing clinical trials,
availability and timing of data from clinical trials and other
factors discussed in the “Risk Factors” section of the Company’s
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
other reports filed with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent the Company’s views as of the date hereof. The
Company anticipates that subsequent events and developments will
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181227005037/en/
Monique AllaireTHRUST Strategic
Communicationsmonique@thrustir.com617-895-9511Alicia DavisTHRUST
Strategic Communicationsalicia@thrustir.com910-620-3302
Sesen Bio (NASDAQ:SESN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sesen Bio (NASDAQ:SESN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024